Kymera Therapeutics (NASDAQ:KYMR) CEO Sells $9,223,200.00 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) CEO Nello Mainolfi sold 80,000 shares of the company’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $115.29, for a total value of $9,223,200.00. Following the transaction, the chief executive officer owned 666,568 shares of the company’s stock, valued at approximately $76,848,624.72. The trade was a 10.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Nello Mainolfi also recently made the following trade(s):

• On Wednesday, April 29th, Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock. The shares were sold at an average price of $81.18, for a total value of $2,435,400.00.

Kymera Therapeutics Stock Performance

Shares of KYMR opened at $113.51 on Friday. The firm has a fifty day moving average of $87.36 and a 200-day moving average of $83.12. The company has a market cap of $9.34 billion, a price-to-earnings ratio of -31.80 and a beta of 1.95. Kymera Therapeutics, Inc. has a 1 year low of $36.65 and a 1 year high of $130.05.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings data on Thursday, April 30th. The company reported ($0.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.18. The business had revenue of $34.37 million for the quarter, compared to analysts’ expectations of $8.27 million. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The company’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same quarter last year, the company earned ($0.82) EPS. Analysts predict that Kymera Therapeutics, Inc. will post -3.28 EPS for the current year.

Key Stories Impacting Kymera Therapeutics

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Seeking Alpha upgraded Kymera Therapeutics to Buy, citing strong pipeline progress, a roughly $1.5 billion cash position, and accelerated timing for KT-621 Phase 2b topline data by year-end 2026. The article argues the oral STAT6 degrader could compete in a large atopic dermatitis market and challenge injectable therapies. Article Title
• Positive Sentiment: Another Seeking Alpha note said Kymera is building toward a key 2H 2026 inflection point, with KT-621’s Phase 2b readout seen as a major catalyst. The commentary also highlighted rapid enrollment, a strong balance sheet, and possible partnership upside. Article Title
• Neutral Sentiment: Analysts continue to rate KYMR favorably overall, with the consensus still at Moderate Buy and recent target increases from firms including Truist and Canaccord Genuity suggesting confidence in the company’s pipeline and long-term prospects.
• Negative Sentiment: Recent insider sales from CEO Nello Mainolfi, CFO Bruce N. Jacobs, and insider Noah Goodman may weigh on sentiment, as the transactions were sizable and follow additional selling earlier in the quarter. Article Title

Institutional Trading of Kymera Therapeutics

Large investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC boosted its stake in shares of Kymera Therapeutics by 169.1% during the 4th quarter. SG Americas Securities LLC now owns 22,693 shares of the company’s stock worth $1,766,000 after acquiring an additional 14,261 shares in the last quarter. Hudson Bay Capital Management LP raised its position in shares of Kymera Therapeutics by 362.7% during the third quarter. Hudson Bay Capital Management LP now owns 23,134 shares of the company’s stock worth $1,309,000 after purchasing an additional 18,134 shares during the period. Eagle Health Investments LP acquired a new stake in shares of Kymera Therapeutics during the fourth quarter worth $10,606,000. State of New Jersey Common Pension Fund D purchased a new stake in shares of Kymera Therapeutics during the fourth quarter valued at $2,610,000. Finally, Holocene Advisors LP purchased a new stake in shares of Kymera Therapeutics during the third quarter valued at $47,563,000.

Analyst Upgrades and Downgrades

KYMR has been the topic of several analyst reports. Brookline Capital Markets restated a “buy” rating on shares of Kymera Therapeutics in a research report on Monday, June 8th. Loop Capital set a $97.00 price target on Kymera Therapeutics in a report on Monday, June 8th. Morgan Stanley reaffirmed an “overweight” rating and issued a $119.00 price objective on shares of Kymera Therapeutics in a report on Thursday, April 30th. Wall Street Zen raised shares of Kymera Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 2nd. Finally, Truist Financial upped their price target on shares of Kymera Therapeutics from $116.00 to $136.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Kymera Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $121.41.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.